Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK), Professor of Medicine at Weill Medical School at Cornell University, and Adjunct Professor in Medical Diplomacy at Trinity College Dublin in Dublin, Ireland.

Professor Abou-Alfa completed his undergraduate studies with a major in biology, and his medical doctorate training at the American University in Beirut (AUB). Professor Abou-Alfa completed his postdoctoral training in internal medicine, medical oncology, and hematology at Yale University. He received his MBA from Columbia University and is completing his JD from Fordham University.

Professor Abou-Alfa specializes in in the treatment of gastrointestinal malignancies and in particular, hepatocellular carcinoma (HCC), intrahepatic and extrahepatic cholangiocarcinoma (IHC), gallbladder cancer (GB), and fibrolamellar carcinoma (FLC). Professor Abou-Alfa leadership effort in the field led to the FDA and other agencies approval of several checkpoint inhibitors and tyrosine kinase inhibitors and biologic targeted therapies

Professor Abou-Alfa is the immediate previous Chair of the National Cancer Institute (NCI) Hepatobiliary Task Force and currently serves at the NCI AIDS Malignancy Consortium (AMC) Vice-Chair for Solid Tumor Working Group. Professor Abou-Alfa serves on the council of the governing board of the Asia Pacific Primary Liver Cancer Expert Association.